FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799863868> ?p ?o ?g. }

• W2799863868 endingPage "1991.e3" @default.
• W2799863868 startingPage "1983" @default.
• W2799863868 abstract "Background & AimsIncreased de novo lipogenesis (DNL) contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase catalyzes the rate-limiting step in DNL. We evaluated the safety and efficacy of GS-0976, a small molecule inhibitor of acetyl-CoA carboxylase, in patients with NASH.MethodsIn an open-label prospective study, patients with NASH (n = 10) received GS-0976 20 mg orally once daily for 12 weeks. NASH was diagnosed based on a proton density fat fraction estimated by magnetic resonance imaging (MRI-PDFF) ≥10% and liver stiffness by magnetic resonance elastography (MRE) ≥2.88 kPa. The contribution from hepatic DNL to plasma palmitate was measured by 14 days of heavy water labeling before and at the end of treatment. We performed the same labelling protocol in an analysis of healthy volunteers who were not given DNL (controls, n = 10). MRI-PDFF and MRE at baseline, and at weeks 4 and 12 of GS-0976 administration, were measured. We analyzed markers of liver injury and serum markers of fibrosis.ResultsThe contribution of hepatic DNL to plasma palmitate was significantly greater in patients with NASH compared with controls (43% vs 18%) (P = .003). After 12 weeks administration of GS-0976, the median hepatic DNL was reduced 22% from baseline in patients with NASH (P = .004). Compared with baseline, reductions in MRI-PDFF at week 12 (15.7% vs 9.1% at baseline; P = .006), liver stiffness by MRE (3.4 kPa vs 3.1 kPa at baseline; P = .049), TIMP metallopeptidase inhibitor 1 (275 ng/mL vs 244 ng/mL at baseline; P = .049), and serum level of alanine aminotransferase (101 U/L vs 57 U/L at baseline; P = .23) were consistent with decreased hepatic lipid content and liver injury. At week 12, 7 patients (70%) had a ≥30% decrease in MRI-PDFF.ConclusionIn an open-label study, patients with NASH given GS-0976 for 12 weeks had reduced hepatic DNL, steatosis, and markers of liver injury. ClinicalTrials.gov no: NCT02856555. Increased de novo lipogenesis (DNL) contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase catalyzes the rate-limiting step in DNL. We evaluated the safety and efficacy of GS-0976, a small molecule inhibitor of acetyl-CoA carboxylase, in patients with NASH. In an open-label prospective study, patients with NASH (n = 10) received GS-0976 20 mg orally once daily for 12 weeks. NASH was diagnosed based on a proton density fat fraction estimated by magnetic resonance imaging (MRI-PDFF) ≥10% and liver stiffness by magnetic resonance elastography (MRE) ≥2.88 kPa. The contribution from hepatic DNL to plasma palmitate was measured by 14 days of heavy water labeling before and at the end of treatment. We performed the same labelling protocol in an analysis of healthy volunteers who were not given DNL (controls, n = 10). MRI-PDFF and MRE at baseline, and at weeks 4 and 12 of GS-0976 administration, were measured. We analyzed markers of liver injury and serum markers of fibrosis. The contribution of hepatic DNL to plasma palmitate was significantly greater in patients with NASH compared with controls (43% vs 18%) (P = .003). After 12 weeks administration of GS-0976, the median hepatic DNL was reduced 22% from baseline in patients with NASH (P = .004). Compared with baseline, reductions in MRI-PDFF at week 12 (15.7% vs 9.1% at baseline; P = .006), liver stiffness by MRE (3.4 kPa vs 3.1 kPa at baseline; P = .049), TIMP metallopeptidase inhibitor 1 (275 ng/mL vs 244 ng/mL at baseline; P = .049), and serum level of alanine aminotransferase (101 U/L vs 57 U/L at baseline; P = .23) were consistent with decreased hepatic lipid content and liver injury. At week 12, 7 patients (70%) had a ≥30% decrease in MRI-PDFF. In an open-label study, patients with NASH given GS-0976 for 12 weeks had reduced hepatic DNL, steatosis, and markers of liver injury. ClinicalTrials.gov no: NCT02856555." @default.
• W2799863868 created "2018-05-17" @default.
• W2799863868 creator A5009422918 @default.
• W2799863868 creator A5013219986 @default.
• W2799863868 creator A5025819859 @default.
• W2799863868 creator A5027014361 @default.
• W2799863868 creator A5031221529 @default.
• W2799863868 creator A5032992878 @default.
• W2799863868 creator A5035876654 @default.
• W2799863868 creator A5042613443 @default.
• W2799863868 creator A5045664376 @default.
• W2799863868 creator A5047114493 @default.
• W2799863868 creator A5053405300 @default.
• W2799863868 creator A5057486794 @default.
• W2799863868 creator A5062064280 @default.
• W2799863868 creator A5064179616 @default.
• W2799863868 creator A5064449939 @default.
• W2799863868 creator A5068192104 @default.
• W2799863868 creator A5075322332 @default.
• W2799863868 creator A5085487679 @default.
• W2799863868 creator A5087596327 @default.
• W2799863868 creator A5088176625 @default.
• W2799863868 creator A5088683463 @default.
• W2799863868 date "2018-12-01" @default.
• W2799863868 modified "2023-10-14" @default.
• W2799863868 title "Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis" @default.
• W2799863868 cites W1850330438 @default.
• W2799863868 cites W1853325270 @default.
• W2799863868 cites W1964572117 @default.
• W2799863868 cites W1967206613 @default.
• W2799863868 cites W1985592156 @default.
• W2799863868 cites W2003518626 @default.
• W2799863868 cites W2016393423 @default.
• W2799863868 cites W2036409621 @default.
• W2799863868 cites W2037918682 @default.
• W2799863868 cites W2039890062 @default.
• W2799863868 cites W2058709828 @default.
• W2799863868 cites W2062812115 @default.
• W2799863868 cites W2086717868 @default.
• W2799863868 cites W2107943478 @default.
• W2799863868 cites W2112377527 @default.
• W2799863868 cites W2137832556 @default.
• W2799863868 cites W2138365442 @default.
• W2799863868 cites W2139351004 @default.
• W2799863868 cites W2168436114 @default.
• W2799863868 cites W2298914518 @default.
• W2799863868 cites W2462595066 @default.
• W2799863868 cites W2546306361 @default.
• W2799863868 cites W2553298154 @default.
• W2799863868 cites W2611949588 @default.
• W2799863868 cites W2619447260 @default.
• W2799863868 cites W2740884150 @default.
• W2799863868 cites W2754550313 @default.
• W2799863868 doi "https://doi.org/10.1016/j.cgh.2018.04.042" @default.
• W2799863868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29705265" @default.
• W2799863868 hasPublicationYear "2018" @default.
• W2799863868 type Work @default.
• W2799863868 sameAs 2799863868 @default.
• W2799863868 citedByCount "141" @default.
• W2799863868 countsByYear W27998638682018 @default.
• W2799863868 countsByYear W27998638682019 @default.
• W2799863868 countsByYear W27998638682020 @default.
• W2799863868 countsByYear W27998638682021 @default.
• W2799863868 countsByYear W27998638682022 @default.
• W2799863868 countsByYear W27998638682023 @default.
• W2799863868 crossrefType "journal-article" @default.
• W2799863868 hasAuthorship W2799863868A5009422918 @default.
• W2799863868 hasAuthorship W2799863868A5013219986 @default.
• W2799863868 hasAuthorship W2799863868A5025819859 @default.
• W2799863868 hasAuthorship W2799863868A5027014361 @default.
• W2799863868 hasAuthorship W2799863868A5031221529 @default.
• W2799863868 hasAuthorship W2799863868A5032992878 @default.
• W2799863868 hasAuthorship W2799863868A5035876654 @default.
• W2799863868 hasAuthorship W2799863868A5042613443 @default.
• W2799863868 hasAuthorship W2799863868A5045664376 @default.
• W2799863868 hasAuthorship W2799863868A5047114493 @default.
• W2799863868 hasAuthorship W2799863868A5053405300 @default.
• W2799863868 hasAuthorship W2799863868A5057486794 @default.
• W2799863868 hasAuthorship W2799863868A5062064280 @default.
• W2799863868 hasAuthorship W2799863868A5064179616 @default.
• W2799863868 hasAuthorship W2799863868A5064449939 @default.
• W2799863868 hasAuthorship W2799863868A5068192104 @default.
• W2799863868 hasAuthorship W2799863868A5075322332 @default.
• W2799863868 hasAuthorship W2799863868A5085487679 @default.
• W2799863868 hasAuthorship W2799863868A5087596327 @default.
• W2799863868 hasAuthorship W2799863868A5088176625 @default.
• W2799863868 hasAuthorship W2799863868A5088683463 @default.
• W2799863868 hasConcept C126322002 @default.
• W2799863868 hasConcept C126838900 @default.
• W2799863868 hasConcept C134018914 @default.
• W2799863868 hasConcept C141359234 @default.
• W2799863868 hasConcept C143409427 @default.
• W2799863868 hasConcept C171089720 @default.
• W2799863868 hasConcept C2776175330 @default.
• W2799863868 hasConcept C2776954865 @default.
• W2799863868 hasConcept C2778772119 @default.
• W2799863868 hasConcept C2779134260 @default.
• W2799863868 hasConcept C2779478299 @default.

• next